Oncobiologics’ (OTLK) Neutral Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their neutral rating on shares of Oncobiologics (NASDAQ:OTLK) in a report issued on Wednesday,Benzinga reports.

A number of other analysts have also recently issued reports on OTLK. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th. Ascendiant Capital Markets raised their price target on Oncobiologics from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. HC Wainwright reissued a “neutral” rating on shares of Oncobiologics in a research note on Wednesday. Finally, Wall Street Zen downgraded Oncobiologics from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.50.

Oncobiologics Stock Performance

Oncobiologics stock opened at $0.41 on Wednesday. Oncobiologics has a twelve month low of $0.38 and a twelve month high of $3.39. The firm has a market cap of $34.32 million, a PE ratio of -0.16 and a beta of 0.10. The firm’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $1.31.

Oncobiologics (NASDAQ:OTLK) last issued its earnings results on Tuesday, February 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The business had revenue of ($1.21) million for the quarter, compared to the consensus estimate of $3.14 million. Equities analysts anticipate that Oncobiologics will post -2.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OTLK. Goldman Sachs Group Inc. lifted its holdings in Oncobiologics by 74.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after buying an additional 21,941 shares during the last quarter. 11.20% of the stock is owned by institutional investors.

Key Headlines Impacting Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Brookline Capital Acquisition raised its Q4 2026 EPS estimate for OTLK to ($0.18) from ($0.22), narrowing the expected quarterly loss — a modest positive signal that one shop sees slightly better near-term performance.
• Neutral Sentiment: HC Wainwright reiterated a “Neutral” rating on Oncobiologics while publishing updated quarterly/annual estimates; the firm remains cautious but did not upgrade or downgrade the stock. HC Wainwright Reaffirms “Neutral” Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: Chardan Capital reiterated its “Neutral” rating on OTLK, signaling no near-term change in analyst stance despite the earnings miss and estimate revisions. Chardan Capital Reiterates Neutral Rating for Oncobiologics (NASDAQ:OTLK)
• Negative Sentiment: HC Wainwright cut FY2026 estimates significantly (FY2026 EPS to ($0.42) from ($0.28)) and trimmed FY2027 to ($0.21) from ($0.19), and nudged Q4 2026 to a larger expected loss — these downward revisions signal weaker near-term profitability expectations and add selling pressure.
• Negative Sentiment: Brookline Capital Acquisition lowered multiple 2026 quarterly and full‑year EPS forecasts (e.g., FY2026 now ($0.79) vs. prior ($0.74); Q2/Q3 2026 also reduced), indicating broader analyst downside revisions across the board.
• Negative Sentiment: Oncobiologics’ recent reported miss (Feb. 17: EPS ($0.22) vs est. ($0.17); revenue sharply below expectations) remains the primary near-term catalyst weighing on the stock—analyst cuts followed the miss and are likely driving continued downward price pressure.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.